The DCGI has formed an expert panel to regulate the use of AI in drug discovery, which will include discussions on evaluation and approval processes.
Why it matters: Understanding the regulation of AI in drug discovery is crucial for exams focusing on science and technology, as well as regulatory frameworks in India.
Formation of Expert Panel
The Central Drugs Standard Control Organisation (CDSCO) has established an expert panel to oversee the use of artificial intelligence (AI) in drug discovery. This initiative was announced by the Drug Controller General of India (DCGI).
Purpose of the Panel
The panel's primary focus is to regulate AI applications within the drug discovery process. It aims to develop guidelines for evaluation and approval processes, ensuring that AI technologies are used effectively and safely in the pharmaceutical sector.
Background on AI in Drug Discovery
AI is increasingly being integrated into drug discovery to enhance efficiency and innovation. However, its use requires careful regulation to address potential risks and ethical concerns, which is why regulatory bodies like CDSCO are stepping in to provide oversight.
Key facts
- CDSCO formed an expert panel.
- Panel to regulate AI in drug discovery.
- DCGI announced the formation.
- Focus on evaluation and approval processes.
In this story
Source: Business Standard